Month: <span>February 2025</span>
Month: February 2025

Sponsor- vs. FDA-Initiated Changes to Pediatric Clinical Trial Protocols: A Comparison of Associated Participant Burden

Ther Innov Regul Sci. 2025 Feb 23. doi: 10.1007/s43441-025-00760-8. Online ahead of print. ABSTRACT INTRODUCTION: Risks associated with clinical trial participation are a foremost consideration …

Guidelines for the use of lung ultrasound to optimise the management of neonatal respiratory distress: international expert consensus

BMC Med. 2025 Feb 24;23(1):114. doi: 10.1186/s12916-025-03879-5. ABSTRACT BACKGROUND: Respiratory distress is the main reason for the admission of infants to the neonatal intensive care …

Population Pharmacokinetics of Cefepime in Critically Ill Children and Young Adults: Model Development and External Validation for Monte Carlo Simulations and Model-Informed Precision Dosing

Clin Pharmacokinet. 2025 Feb 23. doi: 10.1007/s40262-025-01485-5. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVE: This study aimed to develop a population pharmacokinetic model for …

Development and validation of the Parent-Reported Indicator of Developmental Evaluation for Chinese Children (PRIDE) tool

World J Pediatr. 2025 Feb 23. doi: 10.1007/s12519-025-00878-7. Online ahead of print. ABSTRACT BACKGROUND: Developmental delay (DD) poses challenges to children’s overall development, necessitating early …

STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosis

Cell Death Dis. 2025 Feb 23;16(1):125. doi: 10.1038/s41419-025-07456-9. ABSTRACT Axitinib resistance remains a serious challenge in the treatment of advanced renal cell carcinoma (RCC), and …

Expert-Agreed Practical Recommendations on the Use of Fenfluramine in Developmental and Epileptic Encephalopathies Based on Clinical Experience and Literature Review

Neurol Ther. 2025 Feb 23. doi: 10.1007/s40120-025-00713-1. Online ahead of print. ABSTRACT INTRODUCTION: Fenfluramine (FFA) represents the latest therapeutic option approved for seizure management in …